Editas Medicine Reports Inducement Grants to New Chief Financial Officer

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. EDIT, a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Chief Financial Officer, Michelle Robertson. In connection with Ms. Robertson's appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Ms. Robertson as inducements material to Ms. Robertson entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.65 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Robertson's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Ms. Robertson's continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Ms. Robertson's employment start date until the fourth anniversary of Ms. Robertson's employment start date, subject to Ms. Robertson's continued service to Editas Medicine through the applicable vesting dates.

Contacts:
Media
Cristi Barnett
(617) 401-0113 
cristi.barnett@editasmed.com

Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com